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ABSTRACT 
The free fatty acid receptor 2 (FFA2/GPR43) is considered a potential target for treatment of 
metabolic and inflammatory diseases. Here we describe the development of the first fluorescent 
tracer for FFA2 intended as a tool for assessment of thermodynamic and kinetic binding 
parameters of unlabeled ligands. Starting with a known azetidine FFA2 antagonist, we used a 
carboxylic acid moiety known not to be critical for receptor interaction for the attachment of a 
nitrobenzoxadiazole (NBD) fluorophore. This led to the development of 4 (TUG-1609), a potent 
fluorescent tracer for FFA2 with good spectroscopic properties, high affinity as determined by 
saturation and kinetic binding experiments, and high specific to non-specific binding to 
NanoLuciferase (Nluc) tagged FFA2. A BRET-based competition binding assay with 4 was 
established and used to determine binding constants and kinetics of unlabeled ligands.  
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INTRODUCTION 
The free fatty acid receptor 2 (FFA2, also known as GPR43) is a 7-transmembrane receptor 
activated by short-chain fatty acids (SCFAs) produced endogenously during colonic fermentation 
of dietary fiber by the gut microbiota.1-4 The receptor is expressed in various cell types such as 
adipocytes and pancreatic β-cells.5,6 FFA2 is also expressed in immune cells, including 
neutrophils, eosinophils, B lymphocytes, and peripheral blood mononuclear cells, and has been 
shown to mediate SCFA-promoted chemotaxis in neutrophils.7-10 In recent years FFA2 has 
attracted much attention as a possible target for treatment of obesity,11 inflammation,8,12,13 and 
metabolic diseases.4,14 It has however frequently been unclear if the preferred mode of action 
was agonism or antagonism.2 It has been shown that the loss of FFA2 and the related SCFA 
receptor FFA3 (GPR41) leads to increased insulin secretion and improved glucose tolerance, 
indicating a therapeutic potential of antagonists against metabolic diseases.6 The role of the 
receptor in chemotaxis of neutrophils has also suggested anti-inflammatory potential of 
antagonists. For example, the FFA2 antagonist GLPG0974 (1, Chart 1) has been demonstrated to 
inhibit human neutrophil recruitment in vitro and in vivo, suggesting that the compound could 
represent a potential therapeutic for treatment of inflammatory diseases.12,15 Clinical trials with 1 
for treatment of ulcerative colitis indeed showed decreased neutrophil infiltration although no 
significant improvement of symptoms was observed in the patients.16 To fully assess the 
therapeutic potential of FFA2, high quality tool compounds are needed for further investigations 
of FFA2 pharmacology and function. 
Fluorescent tracer molecules have been established as useful tools for real-time monitoring of 
receptor-ligand interactions and offer several advantages over conventional radioactive 
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tracers.17,18 The small, green-emitting fluorophore 4-amino-7-nitrobenzoxadiazole (NBD) has 
previously been employed for labeling small molecules and proteins and has been applied in 
competition binding assays and for imaging of living cells.19,20 Its absorption and emission 
maxima, around 470 nm and 530 nm, respectively, are above the cellular autofluorescence range 
and therefore make NBD a useful probe for in vitro biological studies.21 The fluorescence of 
NBD is almost completely quenched in polar and protic solvents, whereas high fluorescence 
activity is preserved in non-polar environments, which can amplify signal to noise ratio for the 
bound NBD.22 Bioluminescence resonance energy transfer (BRET) interaction between a tagged 
receptor and a fluorescent ligand is useful for real-time interaction monitoring, also between 
GPCRs and small molecules.23 We have recently taken advantage of the properties of NBD by 
developing two free fatty acid receptor 1 (FFA1) fluorescent tracers as well as a BRET 
competition binding assay to NanoLuciferace (NLuc) tagged FFA1 and demonstrated its 
usefulness for investigating the binding of natural and synthetic ligands to the FFA1 receptor.18 
Recognizing the need for a similar fluorescent tracer and assay for FFA2, we aimed to follow an 
equivalent strategy for this receptor. We here report on the design, synthesis and characterization 
of the first fluorescent tracer for FFA2 and the use of the tracer in a BRET competition binding 
assay. The carboxylic acid chain of 1 was originally introduced to tackle ADME issues in the 
compound series.12 Although the carboxylate contributes somewhat to potency of the compound 
and has been demonstrated to depend on the presence of at least one of the two orthosteric 
arginine residues, the group is not required for the activity of the compound.24 The closely 
related azetidine analogue 2 as well as its methyl ester (3) are also efficient FFA2 
antagonists.12,24 As the carboxylic acid group appeared to be dispensable for the affinity of the 
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compounds, we decided to explore this group as attachment point for an NBD fluorophore in the 
design of the proposed FFA2 fluorescent tracer 4 (Chart 1). 
  
Chart 1. Design strategy for an antagonist-based FFA2 fluorescent tracer.  
 
RESULTS AND DISCUSSION 
Synthesis 
The fluorescent tracer 4 was synthesized in 13 steps from commercial starting materials. 
Azetidine 5 was synthesized according to the procedures described by Pizzonero and co-workers 
(Scheme 1).12 Benzothiene-3-acetic acid 6 was activated with bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOP-Cl) and coupled with 5 to give 3. Methyl ester 3 was 
hydrolyzed to carboxylic acid 2, activated using BOP-Cl and coupled to mono-Boc-protected 
1,3-diaminopropane to give 7. Boc-deprotection afforded the crude amine, which was reacted 
directly with NBD-Cl in a nucleophilic aromatic substitution to give the fluorescent 4 in 47% 
yield after purification by preparative HPLC.18 
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Scheme 1. Synthesis of 4.a 
 
aReagents and conditions: (i) Et3N, BOP-Cl, DCM, 80 °C, 25 h, 40%; (ii) LiOH, THF, water, 
rt, 96%; (iii) a): Et3N, BOP-Cl, DCM, 50°C, 3 h; b): Et3N, tert-butyl (3-aminopropyl)carbamate, 
30 min at 50 °C, then rt overnight, 46%; (iv) TFA, DCM, rt; (v) NBD-Cl, NaHCO3, MeOH, 50 
°C, 4 h, 38% over 2 steps. 
 
Characterization of Fluorescent Properties 
Absorbance and fluorescence spectra of 4 were recorded in PBS and in n-octanol, with the 
latter solvent emulating the environment of a predominately hydrophobic receptor binding site or 
membrane.25 A shift of 30 nm was observed when comparing the maximum absorption of 4 in n-
octanol (λmax = 462 nm) with that in PBS buffer (λmax = 492 nm, spectrum not shown). The 
extinction coefficient (ε) of 4 at its maximum excitation wavelength was determined (ε462 nm = 
12,550 M-1 cm-1) from absorbance spectra recorded in n-octanol at increasing concentrations of 4 
(Table 1). Fluorescent tracer 4 exhibits maximum emission at 525 nm with a Stokes shift of 63 
nm and a quantum yield (Φ) of 0.62 in n-octanol (Table 1 and Figure 2A), whereas the 
fluorescence was almost absent in PBS (Figure 2B). Overall, 4 demonstrated properties 
comparable to the values observed for the recently reported NBD-based FFA1 tracers.18 
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Table 1. Fluorescent properties of 4. 
n-Octanol PBS buffer (pH 7.4) 
λex 
[nm] 
λem 
[nm] 
SS 
[nm] 
ε462 nm  
[M-1 cm-1] 
Φ λex  
[nm] 
λem  
[nm] 
462 525 63 12,550 ± 276 0.62 492 557 
aSS, Stokes shift; Φ, quantum yield. 
 
     
Figure 2. Absorbance and fluorescent properties of 4. A) Normalized exitation (dotted line) and 
emission (solid line) spectra in n-octanol. B) Effect of solvent on fluorescence activity of 4 in n-
octanol (black curve) and PBS buffer (blue curve). 
 
Functional Characterization of 4 on FFA2 
Tracer 4 was found to act as an antagonist of propionate (C3)-mediated elevation of inositol 
monophosphate (IP1) levels in Flp-InTM T-RExTM 293 cells induced to express a form of human 
FFA2 that had enhanced Yellow Fluorescent Protein linked in frame to the intracellular C-
terminal tail of the receptor (hFFA2-eYFP) (Figure 3A). The ability of 4 to inhibit the effects of 
an EC80 concentration of C3 was similar to that of the related clinically tested FFA2 antagonist 1 
and analogue 2 (Figure 3A, Table 2). Furthermore, in membrane preparations derived from these 
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cells, increasing concentrations of 4 were able to prevent specific binding of [3H]-1 to the 
hFFA2-eYFP construct with affinity akin to that of unlabeled 1 (pKi = 7.76 ± 0.11) and 2 (Figure 
3B, Table 2). 
  
 
Figure 3. (A) Functional characterization of 4 against 1 and 2 in IP1 accumulation assay. (B) 
Displacement of [3H]-1 using 1, 2 and 4.  
 
Table 2. Characterization of antagonist properties and affinities of unlabeled carboxylic acid 1, 
methyl ester 2 and fluorescent tracer 4 as antagonist in functional IP1 and radioligand 
displacement assays. 
Cmpd pIC50 (IP1)
a pKi (Displacement)
b 
1 6.94 ± 0.04 7.76 ± 0.11 
2 7.08 ± 0.05 7.64 ± 0.08 
4 6.57 ± 0.10 7.31 ± 0.06 
aThe ability of 4 to inhibit IP1 accumulation at EC80 concentration of propionate.
 bKi was 
determined in a [3H]-1 displacement assays.  
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Characterization of 4 as an FFA2 Tracer Molecule 
A saturation binding experiment was performed by adding varying concentrations of 4 to 
membrane preparations generated from Flp-InTM T-RExTM 293 cells induced to express a form of 
human FFA2 that has an NLuc enzyme incorporated into the extracellular N-terminal domain of 
the receptor. This allowed BRET (Figure 4A) between NLuc and the NBD domain of bound 4. 
Subtraction of signal obtained when the same concentrations of 4 were co-incubated with 50 µM 
1 was used to define non-specific binding of 4 (Figure 4A) and to generate a monophasic binding 
curve with an estimated Kd for 4 of 65.1 ± 1.8 nM (Figure 4B). Following addition of 100 nM 4 
to membrane preparations and waiting 2 hours to allow binding to reach equilibrium, wash-out 
of unbound 4 allowed the dissociation of 4 to be monitored under conditions of infinite dilution 
by the reduction of specific BRET signal over time (Figure 4C). Time courses of development of 
specific BRET signals following addition of different concentrations of 4 showed the estimated 
ligand association rate to increase with ligand concentration as predicted by mass action (Figure 
4D). These experiments allowed the determination of a dissociation constant koff of 0.0249 ± 
0.0009 min-1 and an association constant kon of 368,000 ± 29300 M
-1 min-1 for tracer 4. Using 
these constants to independently calculate the affinity of 4 yielded a Kd of 67.7 nM, a value very 
close to that obtained from the saturation binding experiment. 
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Figure 4. (A) BRET-based saturation binding experiment of tracer 4 bound to NLuc tagged 
FFA2 (Total binding); BRET between 4 and NLuc tagged FFA2 recorded using non-fluorescent 
1 at high concentration (10 µM) (non-specific binding). (B) Monophasic binding curve for 4 
obtained by subtracting total binding from non-specific binding of 4. (C) Dissociation of 4 
monitored under conditions of infinite dilution. (D) Time courses measuring the association of 4 
to NLuc tagged FFA2 at varying concentrations of 4. 
 
To compare the usefulness of 4 with that of the radiolabeled FFA2 antagonist [3H]-1, we 
employed the BRET signal produced by 4 bound specifically to NLuc tagged FFA2 in the 
presence of varying concentrations of either 1 or the FFA2 antagonist CATPB (8) as a means to 
concomitantly measure both ‘on’ and ‘off’ rates of these unlabeled ligands (Table 3). Antagonist 
8 is structurally different from 1 but is known to bind to the same site at the FFA2 receptor.24,26 
Previous studies using [3H]-1 indicated that although these two compounds have similar affinity 
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at human FFA2, 8 is relatively ‘fast on-fast off’ whilst 1 displays both slower association and 
slower dissociation kinetics.24 These features were reproduced and confirmed when employing 4 
in such binding kinetic analyses (Figure 5). The rate constants corresponded to dissociation 
constants of 46.9 nM and 18.9 nM for 1 (Figure 5A) and 8 (Figure 5B), respectively (Table 3). 
 
Figure 5. Application of 4 in binding kinetic analyses of unlabeled ligands; (A) 1, (B) 8.  
Table 3. Kinetic properties for fluorescent tracer 4 and unlabeled ligands 1 and 8.  
Cmpd koff (min
-1) kon (M
-1 min-1) Kd (nM) 
4a 0.0249 ± 0.0009 368,000 ± 29300 65.1 
1b 0.0099 ± 0.0014 211,000 ± 4780 46.9 
8b 0.0205 ± 0.0010 1,083,000 ± 59800 18.9 
aRate constants and dissociation constant of 4 determined in BRET-based saturation binding 
assay. bRate constant and dissociation constants for unlabeled ligands 1 and 8 determined using 
tracer 4 in BRET-based competition binding assay. 
 
Importantly, when varying concentrations of 4 were co-added with a range of concentrations of 
1, analysis of the binding of 4, as reported by the specific BRET signal, was consistent with 
competition between the ligands to bind to the receptor (Figure 6A).  Higher concentrations of 4 
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required increasing concentrations of 1 to compete for the receptor binding site (Figure 6A, 
Table 4). Equivalent conclusions were reached for 8 (Figure 6B) and provided an estimated 
affinity for human FFA2 of 14.5 nM, almost identical to the value determined previously when 
employing [3H]-1.24 Notably, affinity values for 1 and 8 determined using 4 in competition 
binding experiments (Table 4) were found to be internally consistent with dissociation constants 
obtained when using 4 in binding kinetic analyses (Table 3). To be useful as a ligand with which 
to screen novel chemical ligands for affinity at human FFA2, it is important that employing 4 
should result in ligand structure activity relationships (SAR) as anticipated from other studies. It 
is known that replacement of the carboxylate moiety of 8 by methyl ester (9) reduces affinity at 
hFFA2 by more than 10 fold.24 Herein, using 4 this expectation was again fulfilled (Figure 6C) 
with 9 displaying 23.6 fold lower affinity for human FFA2, when compared to 8. 
   
 
Figure 6. Application of 4 in competition binding experiments of unlabeled ligands (A) 1, (B) 8, 
(C) 9. 
 
 
 
Table 4. Competition binding affinities of selected FFA2 antagonists. 
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1 8 9 
Affinity 
pKi 7.16 ± 0.06 7.84 ± 0.04 6.42 ± 0.03 
(nM) 69.2 14.5 380 
 
 
CONCLUSION 
By taking advantage of SAR information on known antagonists for FFA2, the fluorescent 
tracer molecule 4 was developed. Tracer 4 contains an NBD fluorescent probe and exhibits 
desirable spectroscopic properties, including a Stokes shift of 63 nm, low fluorescence activity in 
aqueous solution, and a high quantum yield in non-polar environments. Using an NLuc construct 
built into the extracellular N-terminal domain of the FFA2 receptor and BRET-based binding 
experiments, tracer 4 was found to exhibit a Kd of 65 nM and low non-specific binding. The 
BRET binding assay with 4 was further applied to determine thermodynamic and kinetic binding 
parameters of unlabeled FFA2 ligands, resulting in values comparable to those obtained 
previously using a radiolabeled ligand. Compound 4 is the first fluorescent tracer for FFA2 and 
is expected to be useful tool for further studies of the receptor as well as for characterization of 
FFA2 ligands. 
 
EXPERIMENTAL SECTION 
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Synthesis 
Commercial staring materials and solvents were used without further purification, unless 
otherwise stated. THF was freshly distilled from sodium/benzophenone, and MeOH and DCM 
were dried over 3 Å sieves. TLC was performed on TLC Silicage 60 F254 plates and visualized 
at 254 or 365 nm or by staining with ninhydrin or KMnO4 stains. Purification by flash 
chromatography was carried out using silica gel 60 (0.040-0.063 mm, Merck). 1H and 13C NMR 
spectra were recorded at 400 and 101 MHz, respectively, on Bruker Avance III 400 at 300 K. 
Rotamer peaks have been assigned by asterisk (*). Purity was determined by HPLC and 
confirmed by inspection of NMR spectra (1H and 13C NMR). HPLC analysis was performed 
using a Gemini C18 column (5 μm, 4.6x150 mm); flow: 1 mL/min; 10% MeCN in water (0-1 
min), 10-100% MeCN in water (1-10 min), 100% MeCN (11-15 min), with both solvents 
containing 0.1% HCOOH as modifier; UV detection at 254 nm. HPLC purification was 
performed by using a Phenomenex Luna C18 column (5 µm, 250×21.20 mm) with gradient 
elution of MeCN and water, with both solvents containing 0.1% HCOOH as modifier. High-
resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF-Q II (ESI). 
Compounds 1, 8 and 9 were synthesized according to published procedures.12,27  
 
Methyl 4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-(trifluoromethyl)benzyl)-
azetidine-2-carboxamido)butanoate (3). 
In a dry microwave vial carboxylic acid 6 (57.4 mg, 0.30 mmol) and amine 5 (93.4 mg, 0.23 
mmol) were suspended in dry DCM (0.45 mL). To the stirred suspension were added Et3N (175 
μL, 1.26 mmol) and BOP-Cl (88.5 mg, 0.348 mmol), and the vial was heated at 80 °C for 25 h. 
The reaction was cooled to rt, vented, water was added, and the mixture extracted with DCM 
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(x5). The extract was dried over Na2SO4 and concentrated in vacuo. The product was obtained 
after flash chromatography (EtOAc:PE 4:1  100% EtOAc) as a pale yellow sticky oil (50.2 
mg, 40%): Rf = 0.26 (EtOAc); 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.53 (m, 4H), 7.50 – 7.12 
(m, 5H), 4.94 – 4.26 (m, 2H), 4.10 – 2.96 (m, 6H), 3.66* (s, 3H), 3.63 (s, 3H), 2.63 – 2.46 (m, 
1H), 2.43 – 2.14 (m, 3H), 2.00 – 1.71 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 172.6, 172.0, 
169.7, 141.4, 140.3, 139.3, 138.8, 130.1, 128.0, 126.9, 126.3, 125.8, 124.5, 124.3, 124.1, 124.0, 
123.8, 122.9, 122.8, 122.1, 121.8, 71.0, 51.9, 51.8, 46.7, 46.3, 43.1, 34.4, 33.7, 31.3, 30.7, 29.4, 
29.1, 23.8, 23.1; ESI-HRMS calcd for C28H29F3N2NaO4S (M + Na
+) 569.1692, found 569.1714. 
 
4-(1-(2-(Benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-(trifluoromethyl)benzyl)azetidine-
2-carboxamido)butanoic acid (2). 
Compound 3 (50 mg, 91 μmol) dissolved in THF (1 mL) was added 0.6 M aqueous LiOH 
(0.45 mL) and stirred for 3.5 h at rt, whereafter the reaction mixture was acidified with 1 M HCl 
until pH 2-3 and extracted with EtOAc (x3). The extract was washed with brine, dried over 
Na2SO4, and concentrated in vacuo to give the desired product as a sticky oil (46.9 mg, 96%); 
1H 
NMR (400 MHz, CDCl3) δ 7.93 – 7.51 (m, 4H), 7.49 – 7.13 (m, 5H), 4.93 – 4.26 (m, 2H), 4.09 – 
2.95 (m, 6H), 2.61 – 2.43 (m, 1H), 2.40 – 2.12 (m, 3H), 2.00 – 1.70 (m, 5H); 13C NMR (101 
MHz, CDCl3) δ 172.6, 172.6, 170.2, 140.3, 140.3, 139.3, 138.8, 130.1, 129.9, 128.0, 127.0, 
125.8, 124.6, 124.3, 124.1, 124.0, 122.9, 122.8, 122.2, 122.0, 121.8, 71.3, 46.7, 46.2, 43.3, 34.3, 
33.6, 30.5, 29.8, 29.5, 29.0, 25.3, 23.7; ESI-HRMS calcd for C27H27F3N2NaO4S (M + Na
+) 
555.1536, found 555.1544; HPLC: tR = 11.80 min, 97.1%. 
1H NMR in overall agreement with 
literature.12 
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tert-Butyl-(3-(4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-(trifluoromethyl)-
benzyl)azetidine-2-carboxamido)butanamido)propyl)carbamate (7). 
The crude carboxylic acid 2 (40 mg, 75 μmol) in dry DCM (150 μL) was added Et3N (20 μL, 
150 μmol) followed by BOP-Cl (23.9 mg, 94 μmol), and the reaction was heated slowly to 50 
°C. After 3 h, additional Et3N (25 μL, 188 μmol) was added followed by tert-butyl (3-
aminopropyl)carbamate (17 mg, 1.0 mmol). The reaction was stirred at 50 °C for 30 min, cooled 
to rt, and stirred over night before concentration in vacuo and purification of the crude product 
by flash chromatography (DCM [5% MeOH]) to yield the desired product as clear sticky oil 
(23.9 mg, 46%): Rf = 0.12 (DCM [5% MeOH]); 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.51 (m, 
4H), 7.49 – 7.13 (m, 5H), 7.24 – 7.11 (m, 1H), 6.79 – 6.40 (m, 1H), 4.92 – 4.49 (m, 2H), 4.47 – 
4.27 (m, 1H), 4.24 – 3.84 (m, 3H), 3.78 – 3.38 (m, 2H), 3.26 – 3.16 (m, 2H), 3.14 – 3.00 (m, 
2H), 2.58 – 2.41 (m, 1H), 2.38 – 2.20 (m, 1H), 1.94 – 1.73 (m, 5H), 1.71 – 1.48 (m, 4H), 1.43* 
(s, 9H), 1.42 (s, 9H); ESI-HRMS calcd for C35H43F3N4NaO5S (M + Na
+) 711.2798, found 
711.2786. 
  
1-(2-(Benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-((3-((7-nitrobenzo[c][1,2,5]oxadiazol-
4-yl)amino)propyl)amino)-4-oxobutyl)-N-(4-(trifluoromethyl)benzyl)azetidine-2-
carboxamide (4). 
To a pre-dried microwave vial at rt, the Boc-protected amine 7 (23.9 mg, 35 μmol) was 
dissolved in dry DCM (70 μL) followed by dropwise addition of TFA (66 μL, 0.867 mmol). 
Upon full deprotection indicated by TLC the reaction mixture was diluted with DCM, added 
NaHCO3 (sat), extracted with DCM (x5), the organic phases dried over Na2SO4, and 
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concentrated in vacuo. The crude amine (17 mg) was used in the next step without further 
purification. 
To a pre-dried microwave vial under argon were added crude amine (17 mg), NBD-Cl (17.3 
mg, 87 μmol), NaHCO3 (9.8 mg, 117 μmol) and the reactants were dissolved in dry MeOH (0.7 
mL). The vial was capped, protected from light, and stirred at 50 °C for 4 h. The reaction was 
cooled to rt, concentrated under N2 flow, redissolved in EtOAc (2 mL) and water (2 mL), 
extracted with EtOAc (x3), washed with brine, and concentrated in vacuo. The crude product 
was purified on preparative HPLC using a Phenomenex Luna C18 5 µm column (250×21.20 
mm), with gradient elution of 0.05% TFA/MeCN and 0.05% TFA/H2O at a flow rate of 20 
mL/min. HPLC fractions were concentrated under reduced pressure, the remaining aqueous 
phase extracted with EtOAc (x5), the organic phases washed with brine, and concentrated in 
vacuo to give the desired product as red sticky oil (10.1 mg, 38% over 2 steps): Rf = 0.32 (DCM 
[10%]); 1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.4 Hz, 1H), 8.01 – 7.92 (m, 1H), 7.84 – 7.77 
(m, 1H), 7.72 – 7.67 (m, 1H), 7.63 (d, J = 7.7 Hz, 2H), 7.42 – 7.36 (m, 1H), 7.36 – 7.29 (m, 2H), 
7.28 – 7.24 (m, 1H), 7.23 (br s, 1H), 6.01 (d, J = 8.4 Hz, 1H), 4.67 – 4.58 (m, 1H), 4.36 – 4.25 
(m, 1H), 4.21 – 3.99 (m, 3H), 3.68 – 3.63 (m, 2H), 3.51 – 3.22 (m, 6H), 2.58 – 2.45 (m, 1H), 
2.39 – 2.17 (m, 4H), 1.94 – 1.73 (m, 4H), 1.70 – 1.55 (m, 2H); ESI-HRMS calcd for 
C36H37F3N7O6S (M + H
+) 752.2473, found 752.2502; HPLC: tR = 12.29 min, 99.9%. 
 
Characterization of excitation and emission properties of 4 
Single concentration absorbance and emission spectra of fluorescent tracer 4 was recorded at 
8.82 μM. Extinction coefficient for 4 in n-octanol was recorded using a FLUOstar Omega 
Microplate Reader (BMG labtech). Fluorescence spectra for 4 were recorded in duplicates using 
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a ChronosFD time-resolved spectrofluorometer coupled to PMT detectors. Coumarin 153 (C-
153) and 4 were excited at a fixed excitation wavelength of 402 nm, and C-153 in EtOH was 
used as an internal standard for determination of quantum yield (ΦC-153 = 0.546 λex = 402 nm).28 
All experiments were performed at 25 °C. 
 
IP1 accumulation assay  
All IP1 experiments were performed using Flp-InTM T-RExTM 293 cells able to express 
receptor constructs of interest in an inducible manner. Experiments were carried out using a 
homogeneous time-resolved FRET-based detection kit (Cis-Bio Bioassays, Codolet, France) 
according to the manufacturer’s protocol. Cells were induced to express the receptor of interest 
by treatment for 24 h with 100 ng/mL doxycycline and plated at 7500 cells/well in low-volume 
384-well plates. The ability of C3 to induce accumulation of IP1 was assessed following a co-
incubation for 2 hours with C3, which was preceded by a 15-min pre-incubation with antagonist 
to allow for equilibration. 
 
Radioligand displacement assay 
All receptor radioligand binding experiments using [3H]-1 were conducted in glass tubes, in 
binding buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.4). 
Membrane protein was generated from Flp-InTM T-RExTM 293 cells induced to express the 
receptor construct of interest with 100 ng/mL doxycycline. For [3H]-1 competition binding 
assays, the radioligand at approximately Kd concentration and varying concentrations of 
unlabeled ligand of choice were co-added to 5 µg of membrane protein. Non-specific binding of 
the radioligand was determined in the presence of 10 µM 8. After an incubation period of 2 h at 
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25 °C, bound and free [3H]-1 were separated by rapid vacuum filtration through GF/C glass 
filters using a 24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK), and unbound 
radioligand was washed from filters by three washes with ice-cold PBS. After drying (3–12 h), 3 
mL of Ultima GoldTM XR (PerkinElmer Life Sciences) was added to each sample vial, and 
radioactivity was quantified by liquid scintillation spectrometry. Aliquots of [3H]-1 were also 
quantified to define the concentration of [3H]-1 added per tube. Data were fitted to a one-site 
model using Graphpad Prism v6 and used to calculate pKi values based on a Kd value for [
3H]-
1 of 7.5 nM.16 
 
Equilibrium BRET binding assay 
The NLuc-hFFA2 construct and cell line were developed as described by Christiansen et al.20 
NLuc-hFFA2 Flp-InTM T-RExTM 293 cells were induced to express the receptor construct by 
treating with 100 ng/mL doxycycline for 24 h. Cells were then harvested and used to make total 
cell membrane preparations. Membranes were suspended in binding buffer and transferred into a 
white 96-well plate at 5 μg membrane protein per well. Membranes were then co-incubated with 
the indicated concentration of 4 (and 1 for non-specific binding measurements; or competing 
ligand for competition experiments) for 2 h at 30 °C. Following incubation, the NLuc substrate, 
Nano-Glo (Promega) was added to a final 1:800 dilution. Membranes were incubated a further 5 
min before the bioluminescent emission at 460 and 545 nm was measured using a Clariostar 
plate reader (BMG labtech). Total and non-specific saturation binding data were then globally fit 
to a one-site binding model using Graphpad Prism v6. Competition binding experiments were fit 
to a one-site model and used to calculate pKi values based on a Kd value for 4 of 65.1 nM. 
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Kinetic BRET binding assay 
For kinetic BRET binding assays, cell membranes were generated as for the equilibrium 
binding assay and again distributed in white 96-well microplates (2.5 μg membrane 
protein/well). The Nano-Glo substrate was then added (1:800 final dilution) before incubation 
for 5 min at 30 °C. Plates were then inserted into a Clariostar plate reader, with temperature set 
to 30 °C and set to read emission at 460 and 545 nm at 90 s intervals. For association 
experiments 4 (100 nM final concentration) was manually added to the plate after 60 s. Readings 
were continued at 90 s intervals for the indicated time period. For dissociation experiments the 
reaction was pre-incubated for 2 h at 30 °C followed by two washes with binding buffer, 
performed via centrifugation at 14,000 rpm at 4 °C for 15 min. The pellet was then resuspended 
in binding buffer at 37 °C and transferred into a white 96-well microplate at 90 µL/well and 
standard kinetic binding assay procedure as described above was followed. In all kinetic 
experiments parallel wells were assessed in which 1 had been pre-added, and these were used to 
subtract the non-specific binding signal for 4. Kinetic binding data were then fit to one-phase 
association or dissociation models using Graphpad Prism v6 to obtain estimates of koff, kon, and 
Kd. 
 
Determination of the “On” and “Off” Rates of Unlabeled Ligands through Measurement 
of Competition Binding Kinetics of 6 
The kinetic binding parameters of unlabeled ligands were determined through assessment of 
the binding kinetics of 4 as described above. Here the standard procedure was followed. After 5 
min pre-incubation of membrane protein with Nano-Glo, 6 (100 nM) and three different 
concentrations of competing unlabeled ligand (1-, 3-, and 10-fold the estimated respective Ki 
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concentration) were added simultaneously. Readings were then continued at 90 s intervals for 60 
min. Three different concentrations of competitor were assessed to ensure that the rate 
parameters calculated were independent of ligand concentration. Data were fit globally using the 
kinetics of the competitive binding equation available from GraphPad Prism, with the kon and koff 
values of 4 entered as constraints. 
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